---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000012"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:11:08.189649+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports FY2025 net loss $90.4M, cash $269M; NGN-401 dosing on track

## Summary
- Net loss $90.4M in FY2025 vs $75.1M in FY2024; cash $269M funds through Q1 2028.
- 100% enrolled in Embolden registrational trial for Rett syndrome; >50% dosed; on track to complete dosing Q2 2026.
- NGN-401 generally well-tolerated at 1E15 vg dose, no HLH cases; FDA Breakthrough Therapy designation granted.
- R&D expenses $75.0M up from $60.9M; G&A $28.3M up from $22.6M.
- Key milestones: interim Phase 1/2 data mid-2026, PPQ campaign mid-2026, BLA submission.

## SEC filing metadata
- accession: 0001404644-26-000012
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/0001404644-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/ngne-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000012
- JSON: https://secwatch.observer/filing/0001404644-26-000012.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000012.txt

## Key facts
- Earnings Releases
  Neurogene Inc. reported twelve months ended December 31, 2025 results: net income -90.4 million.
  - Period: twelve months ended December 31, 2025
  - Net income: -90.4 million
  - Result: reported results
  source text: Full Year 2025 Financial Results • Cash, Cash Equivalents and Short-Term Investments : Cash, cash equivalents and short-term investments as of December 31, 2025 were $269.0 million and are expected to fund planned operations through the first quarter of 2028. • Research & Development (R&D) Expenses : R&D expenses were $75.0 million for the twelve months ended December 31, 2025, compared to $60.9 million for the twelve months ended December 31, 2024. The increase in R&D expenses for the twelve months ended December 31, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount, and it was partially offset by decreases in spending on the CLN5 Batten disease program and early discovery. • General & Administrative (G&A) Expenses : G&A expenses were $28.3 million for the twelve months ended December 31, 2025, compared to $22.6 million for the twelve months ended December 31, 2024. The increase in G&A expen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/0001404644-26-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.